Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease

被引:13
|
作者
Bekris, Lynn M. [1 ,2 ]
Millard, Steve [3 ]
Lutz, Franziska [2 ]
Li, Gail
Galasko, Doug R. [5 ,6 ]
Farlow, Martin R. [7 ]
Quinn, Joseph F. [8 ,9 ]
Kaye, Jeffrey A. [8 ,9 ]
Leverenz, James B. [3 ,4 ,10 ]
Tsuang, Debby W. [3 ]
Yu, Chang-En [2 ]
Peskind, Elaine R. [3 ]
机构
[1] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA
[2] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA
[3] VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res Educ & Clin Ct, Seattle, WA USA
[4] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA
[5] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
[6] VA Med Ctr San Diego, San Diego, CA USA
[7] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA
[8] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[9] Portland VA Med Ctr, Portland, OR USA
[10] Parkinsons Dis Res Educ & Clin Ctr PADRECC, NW Network VISN 20, Roseburg, OR USA
关键词
FYN; PPP2R4; MAPT; AD; CSF; PROTEIN-TYROSINE KINASE; FYN KINASE; COGNITIVE IMPAIRMENTS; POLYMORPHISMS; ASSOCIATION; BIOMARKERS; DIAGNOSIS; PP2A; CSF;
D O I
10.1002/ajmg.b.32094
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Alzheimer's disease (AD) is characterized by the presence in the brain of amyloid plaques, consisting predominately of the amyloid beta peptide (A beta), and neurofibrillary tangles, consisting primarily of tau. Hyper-phosphorylated-tau (p-tau) contributes to neuronal damage, and both p-tau and total-tau (t-tau) levels are elevated in AD cerebrospinal fluid (CSF) compared to cognitively normal controls. Our hypothesis was that increased ratios of CSF phosphorylated-tau levels relative to total-tau levels correlate with regulatory region genetic variation of kinase or phosphatase genes biologically associated with the phosphorylation status of tau. Eighteen SNPs located within 5' and 3' regions of 5 kinase and 4 phosphatase genes, as well as two SNPs within regulatory regions of the MAPT gene were chosen for this analysis. The study sample consisted of 101 AD patients and 169 cognitively normal controls. Rs7768046 in the FYN kinase gene and rs913275 in the PPP2R4 phosphatase gene were both associated with CSF p-tau and t-tau levels in AD. These SNPs were also differentially associated with either CSF t-tau (rs7768046) or CSF p-tau (rs913275) relative to t-tau levels in AD compared to controls. These results suggest that rs7768046 and rs913275 both influence CSF tau levels in an AD-associated manner. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:874 / 883
页数:10
相关论文
共 50 条
  • [31] Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease
    Constantinescu, Radu
    Romer, Megan
    Zetterberg, Henrik
    Rosengren, Lars
    Kieburtz, Karl
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (09) : 714 - 715
  • [32] High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
    Malin Degerman Gunnarsson
    Martin Ingelsson
    Kaj Blennow
    Hans Basun
    Lars Lannfelt
    Lena Kilander
    Alzheimer's Research & Therapy, 8
  • [33] High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease
    Gunnarsson, Malin Degerman
    Ingelsson, Martin
    Blennow, Kaj
    Basun, Hans
    Lannfelt, Lars
    Kilander, Lena
    ALZHEIMERS RESEARCH & THERAPY, 2016, 8
  • [34] NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease
    Garcia-Escobar, Greta
    Puig-Pijoan, Albert
    Puente-Periz, Victor
    Fernandez-Lebrero, Aida
    Maria Manero, Rosa
    Navalpotro-Gomez, Irene
    Suarez-Calvet, Marc
    Grau-Rivera, Oriol
    Contador-Munana, Jose
    Cascales-Lahoz, Diego
    Duran-Jorda, Xavier
    Boltes, Nuncia
    Claustre Pont-Sunyer, Maria
    Ortiz-Gil, Jordi
    Carrillo-Molina, Sara
    Dolores Lopez-Villegas, Maria
    Teresa Abellan-Vidal, Maria
    Isabel Martinez-Casamitjana, Maria
    Jose Hernandez-Sanchez, Juan
    Padros-Fluvia, Anna
    Pena-Casanova, Jordi
    Sanchez-Benavides, Gonzalo
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 92 (04) : 1303 - 1321
  • [35] Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
    Lafirdeen, Aysha S. Mohamed
    Cognat, Emmanuel
    Sabia, Severine
    Hourregue, Claire
    Lilamand, Matthieu
    Dugravot, Aline
    Bouaziz-Amar, Elodie
    Laplanche, Jean-Louis
    Hugon, Jacques
    Singh-Manoux, Archana
    Paquet, Claire
    Dumurgier, Julien
    PLOS ONE, 2019, 14 (05):
  • [36] SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
    Cruchaga, Carlos
    Kauwe, John S. K.
    Mayo, Kevin
    Spiegel, Noah
    Bertelsen, Sarah
    Nowotny, Petra
    Shah, Aarti R.
    Abraham, Richard
    Hollingworth, Paul
    Harold, Denise
    Owen, Michael M.
    Williams, Julie
    Lovestone, Simon
    Peskind, Elaine R.
    Li, Ge
    Leverenz, James B.
    Galasko, Douglas
    Morris, John C.
    Fagan, Anne M.
    Holtzman, David M.
    Goate, Alison M.
    PLOS GENETICS, 2010, 6 (09)
  • [37] High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease
    Gunnarsson, M. Degerman
    Lannfelt, L.
    Ingelsson, M.
    Basun, H.
    Kilander, L.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2014, 37 (3-4) : 196 - 206
  • [38] Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease
    Kanai, M
    Shizuka, M
    Urakami, K
    Matsubara, E
    Harigaya, Y
    Okamoto, K
    Shoji, M
    NEUROSCIENCE LETTERS, 1999, 267 (01) : 65 - 68
  • [39] Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease
    Yu, Chao-Chao
    Jiang, Tao
    Yang, Ao-Fei
    Du, Yan-Jun
    Wu, Miao
    Kong, Li-Hong
    NEURAL PLASTICITY, 2019, 2019
  • [40] Plasma tau levels in Alzheimer's disease
    Zetterberg, Henrik
    Wilson, David
    Andreasson, Ulf
    Minthon, Lennart
    Blennow, Kaj
    Randall, Jeffrey
    Hansson, Oskar
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (02):